Favrille, Inc., a biopharmaceutical company, focuses on the development and commercialization of immunotherapies for the treatment of cancer and other diseases of the immune system. It offers FavId, which is in Phase III clinical trials, for the treatment of B-cell non-Hodgkin’s lymphoma. The company’s technology enables in manufacturing immunotherapy products that are designed to stimulate a patient’s immune system to mount a specific and sustained response to diseases. It also develops FAV-201 for the treatment of T-cell lymphoma. In addition, the company intends to initiate preclinical studies to identify additional product candidates...
read more
QUOTE
As of 02:17AM EDT May 24, 2012
$
( )
Today's Open:
Today's Close:
| Today's High: |
|
Volume (thous): |
|
| Today's Low: |
|
Avg Vol (thous): |
|
| 52 Week High: |
|
Bid (size): |
|
| 52 Week Low: |
|
Ask (size): |
|
COMPANY INFO
To see the headquarters in Google Street View &trade, drag this yellow guy:
over to the red pointer:
Company Details:
| Symbol: |
FVRL |
| SIC: |
-
|
| State location: |
CA |
| Sector: |
- |
| State of Inc: |
DE |
| Employees: |
12 |
| Type: |
NASDAQ |
FAVRILLE, INC (FVRL) MESSAGE BOARD
